Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.

Binds to PD-L1.

PD-L1Pep-2 was identified from a phage-displayed library for peptides that selectively bind to PD-L1-overexpressing cells. PD-L1Pep-2 has a binding affinity of 281 nM, and preferentially binds to high PD-L1-expressing cells over low PD-L1-expressing cells, binding further enhanced by interferon-?, an inducer of PD-L1 expression. In animal models, intravenously injected PD-L1Pep-2 efficiently targets tumour tissues, inhibits tumour growth, and increases the CD8+/FoxP3+ ratio in mice. PD-L1Pep-2 in combination with doxorubicin inhibits tumour growth more efficiently than doxorubicin alone. PD-L1Pep-2 blockade of PD-L1 reinvigorates T-cell activity and inhibits tumour growth by enhancing anti-tumour immunity.

Please contact us for availability.